

NOTES FROM THE PRESIDENT

by Kari Atkinson

We want to thank Candi Walz for her service on the Board of Directors. The Board was sorry to accept her resignation but understands that family comes first. We appreciate Candi's hard work as the Board Secretary. Candi also served on several committees and helped our organization grow through her efforts.

I have to tell you a story to explain the photo below. I have personally experienced things in my life that I did not know I would encounter as a Board member of HOI and as an active participant in the hemophilia community. Well, one such thing was meeting with our interim secretary, Emily Weidman, to exchange some HOI printing materials. We met in the town of Brandon, Iowa. We found their "Hillbilly Days" festivities were going on at the same time we were there. You know you are in small town Iowa when people are walking down "main" street as a group with strollers, coolers, etc., and all of them are heading to a location down the block to listen to the band

playing there. As you may know, Brandon is also known for having the "Biggest Frying Pan in Iowa." Just goes to show that with a bleeding disorder in your family, you just don't know what type of experiences you might have—including seeing the Biggest Frying Pan in Iowa!



Although there are no typical inhibitor symptoms, one sign is that factor ceases to control bleeding effectively. Contact your HTC for more information and testing if you suspect an inhibitor!

So, I leave you with this...What have you experienced lately that was not in your normal scope of activities?

2007 CAMP SUPERFLY COMPETITION

*By Peggy A. Wier
Baxter Territory Business Manager*

It is indeed my honor to announce to all of you that **WE DID IT!** Iowa is #1 for this year's Camp SuperFly Competition!! Our fearless leaders have had this prize winning position as a goal since the launch of this program in late Spring. A **\$30,000** grant was given by Baxter to the chapter at the annual meeting in September. This money can be used to add a camp, improve a camp, or provide funding for more kids to attend. As you know, the Camp Tanager pavilion and two years of family camp are examples of how past earnings have been allocated. We have been in the money for three years with Camp SuperFly, and this is the Fir\$T year we finished Fir\$T!

Our co-leaders, Tami Bullock, RN, and Kari Atkinson shared ideas, effort and the competitive spirit essential to our finish. All would agree that Tami's "winning attitude and never-

ending determination” gave us the edge and enabled us to maintain the lead throughout the contest. Kari provided a tremendous amount of support and did everything she could to work with community members and encourage participation. Having been edged out of first in the past two years, “it ain’t over till it’s over.” Not this year!! These results are Final! The formal posting is on the website at www.campsuperfly.com In the meantime, take a look at the winners.

Thank you to all our participants and supporters, YOUR efforts to play and win make this program not only a lot of fun but rewarding to all future campers!!

eNOTES ON IOWA

The following came from eNotes, the National Hemophilia

Foundation’s monthly newsletter for the bleeding and clotting disorders community:

<http://www.hemophilia.org>

Texas Governor Signs Bleeding Disorders Advisory Council Act

On June 15, 2007, Texas Governor Rick Perry signed into law S.B. 1566, the Texas Bleeding Disorders Advisory Council Act. The new law establishes a Bleeding Disorders Advisory Council, which will be appointed jointly by the Commissioners of State Health Services and Insurance. ...Texas is now the second state to have adopted a version of NHF’s model Bleeding Disorders Advisory Board bill since the campaign was announced at its 2007 Washington Days. In March, Iowa was the first state to pass the legislation. Illinois and Massachusetts are considering similar legislation. A decision in Massachusetts is

still pending, after public hearings were held on its version of the bill.

The NHF Public Policy Department is supporting a variety of legislative and other policy initiatives throughout the country to help ensure access to high-quality care for people with bleeding disorders. For more information on our initiatives or to bring an issue to our attention, visit the Advocacy Center on the NHF Web site <http://www.hemophilia.org>, or contact Ruthlyn Noel, NHF Manager of Public Policy: 212.328.3730 or e-mail at rnoel@hemophilia.org.

STUDIES OPEN FOR HEMOPHILIA & THROMBOPHILIA

Baxter Previously Untreated Patients

This study will close to enrollment in Fall, 2007. Subjects may be in the study for 75 exposures or 3 years. Visits are every 3 months. Inclusion criteria are: the subject must be less than 6 years old, the Factor VIII level must be less than 2% and they must have less than 3 exposures to Advate. Exclusion criteria include: exposure to Factor VIII other than Advate; you must not have a detectable Factor VIII inhibitor; you must not be HIV, Hepatitis B or Hepatitis C positive; and you must not have received any blood products.

Data Collection on Complications of Hemophilia and Serum Testing and Storage (CDC/UDC)

The HTC has been involved with this study since 1997. To be a subject, a person must have a diagnosis of hemophilia (either Factor VIII or Factor IX deficiency), von Willebrand Disease, or an acquired inhibitor. The purpose of the study is to monitor the health status of people who are diagnosed with the previously

Congratulations to the winning teams for

CAMP SUPERFLY III!



Climbers	Flyers	Explorers
1 Tri-state / Cincinnati STINGERS	1 Iowa YELLOWJACKETS	1 Lone Star BUTTERFLIES
2 Heartland HORNETS	2 Maryland DRAGONFLIES	2 Southern CA ROCK-ON BEES
3 South Carolina PRAYING MANTISES	3 Oregon TAPAWINGOS	3 Illinois Camp WARREN JYRCH
4 New England YELLOWJACKETS	4 Great Lakes / Wisconsin HONEYBEES	4 Indiana HORNETS
5 Nebraska DRAGONFLIES	5 Louisiana FIREFLIES	5 Tennessee LIGHTNING BUGS
6 Texas Central YELLOWJACKETS	6 Washington DRAGONFLIES	6 Western Pennsylvania MOSQUITOS
7 Oklahoma FIREFLIES	7 Kentucky KRICKETS	7 New Jersey ALL STARS
8 Hawaii LAVA LOCUSTS	8 Arkansas MOSQUITOS	8 Nevada DRAGONFLIES
9 Virginia DRAGONFLIES	9 Delaware Valley BEES	9 North Carolina MONARCHS
10 Rocky Mountain CAMP BIG SKY	10 Greater Florida CRICKETS	10 Central CA DRAGONFLIES
11 Idaho POTATOBUGS	11 Northern CA GREEN HORNETS	

mentioned bleeding disorders. The study is conducted at the time you are seen for your comprehensive hemophilia clinic.

The Second Multicenter Hemophilia Cohort Study (MHCS-II)

To be eligible to enroll in this study you must have diagnoses of a bleeding disorder factor (V, VIII, IX, XI or von Willebrand Disease) and be Hepatitis C positive. The purpose of the study is to evaluate and follow subjects with an inherited bleeding disorder who have been infected with Hepatitis C. It is hoped that this study will improve the understanding of hemophilia care and its complications.

Genetics of Inhibitor Formation in Hemophilia

To be eligible to participate in this study, you have to be diagnosed with a severe Factor VIII deficiency and have a brother who has also been diagnosed with a severe Factor VIII deficiency. In addition, one of you has to have been diagnosed with an inhibitor or had a history of inhibitors. The purpose of the study is to complete laboratory tests to find out whether there are differences from person to person that might explain why some people with hemophilia develop inhibitors and some people do not. Once we have a better understanding of inhibitor development, we will have a better chance to design treatment to get rid of inhibitors or even be able to prevent them from occurring.

International, Randomized, Controlled Trial of Immune-Tolerance Induction

To be eligible to participate in this study you have to be diagnosed with a severe factor VIII deficiency, have a high titer Factor VIII inhibitor,

be less than 7 years old, and your inhibitor will need to be less than 10 BU before you can start the study. The purpose of the study is to compare different treatment plans for the treatment of inhibitors.

Hemophilic Genotype, Inhibitors and Response to Immune Tolerance: A Prospective Companion Study

To be eligible for this study, you have to be less than 7 years old, have been diagnosed with a severe factor VIII deficiency, and have had an inhibitor for less than a year. You would have to be enrolled in the "International, Randomized, Controlled Trial of Immune Tolerance Induction" study to enroll in this study. The purpose of the study is to learn if

certain kinds of genetic structures will predict how someone with a severe Factor VIII deficiency will respond to Factor VIII replacement.

Wyeth BeneFIX Study

This is a prophylactic study for severe Factor IX deficient patients. The subject will participate for 15 months. They will be randomized to 2 different doses of BeneFIX-R.

Wyeth ReFacto AF Surgical Study

Subjects will be given ReFacto AF during a surgical procedure. Pre-surgical lab work will need to be done. Subjects must be older than 12 years of age and their factor VIII level must be equal to or less than 2%.



Deciding where your factor comes from is your choice.

Shouldn't you choose a company that delivers *more than* just a box of factor?

BioRx works hard to earn your trust.

BioRx

3024 Timberline Drive
Riverside, Iowa 52327
www.biorx.net

1.888.44.BIORX
1.888.442.4679

HTRS Registry

The purpose of this study is to learn how to improve treatment for bleeding in persons with inhibitors.

The Hemophilia and Thrombosis Research Society (HTRS) has established a national patient registry through which a common set of data is collected from Hemophilia Treatment Centers (HTCs) to gain a better understanding of the pathophysiology of hemophilia and other coagulation disorders; the current clinical management of patients with these disorders; and the safety and efficacy of alternative treatments.

Role of Genetic Modifiers in Bleeding Disorders (NIH Study)

This study is open to enrollment for people with vWD, Gray Platelet Syndrome and platelet disorders. It requires a one-time visit where you will complete a bleeding questionnaire and have blood drawn.

Thrombophilia Registry

Subjects will be followed for two (2) years after having a thrombophilic episode. There are no study interventions—only data collection.

We will have several new studies beginning in the fall.

Novo Nordisk

Novo Nordisk will have 2 new prophylactic studies for factor VIII deficient patients with inhibitors.

Wyeth

Wyeth will be starting a new study for children under age 6 using ReFacto AF. The subjects will be randomized to one of two prophylactic doses or continue with on-demand treatment. The study will last for two (2) years.

Both Bayer and Baxter are also working on long-acting factor studies.

NEWS FROM THE HTC

by Karla Watkinson, RN

Congratulations to Dr. Jorge Di Paola for obtaining tenure and becoming an Associate Professor in the Department of Pediatrics, Division of Hematology/Oncology, in addition to being the Director of the Hemophilia Treatment Center.

Congratulations to Dr. Steven Lentz on being named the Director of the Hematology/Oncology and Bone Marrow Transplantation Division in the Department of Internal Medicine.

The Hemophilia Treatment Center has been working with Hemophilia of Iowa, Inc., and the First Step Program with events around the state. Watch your mail for future opportunities to participate.

Our 2nd Amish Outreach clinic was completed in Bloomfield in April. It was well attended, and we served 35 people in that community. We are fortunate to be able to provide this service to so many and are able to utilize the Davis County Hospital and their outreach clinic.

The HTC is without a secretary again! Please be patient while we transition through this period. If you think your comprehensive clinic is due; and you have not received a letter notifying you of your appointment date and time, please call the HTC at 1-800-272-3547, option 1 or 2.

PRESS RELEASES

Baxter Presents Data from Ongoing Bleeding Disorders Development Programs at International Congress

Baxter announced data presented at the twenty-first meeting of the International Society of Thrombosis and Haemostasis (ISTH) held July 6-12. ...

FactorCare®...

re-defining
hemophilia therapy
management.




**HEMOPHILIA
HEALTH SERVICES**
...for the human factor

800.922.9440
FactorCare.com

A DIVISION OF ACCREDO HEALTH GROUP, INC.



Finally, there's someone to look out for you.
Because you've got enough on your mind.



We take the worry out of living with hemophilia and other bleeding disorders, so you can enjoy life. We handle prescription fulfillment and product delivery, with a full line of factor products and custom foil-wrap packaging that maintains the recommended temperature in all weather. We also handle insurance reimbursement and care provider issues. You'll have an individual case manager to assist you, advise you and negotiate for you. Finally, you'll have the reassuring feeling of someone always looking out for you. Finally, you'll have peace of mind.

Call us so we can start serving you today.

Craig MacDonald - 888-522-3681 ♦ Jim Brown - 888-550-1597



Mid-West Cornerstone Healthcare, P.O. Box 771038, St. Louis, MO 63177

www.mwcornerstone.com

Abstract Numbers P-T-194, P-W-197, P-W-196

Baxter researchers presented three pre-clinical studies characterizing a candidate blood-free recombinant human von Willebrand factor. In biochemical assays, the therapeutic protein candidate was shown to have properties similar to a plasma-derived product. Furthermore, in several in vivo models of von Willebrand disease, it showed comparable efficacy. Clinical studies will be conducted to confirm these results.

Abstract Number O-M-018

Baxter researchers presented results of pre-clinical studies evaluating the properties of a pegylated form of recombinant vWF therapy as a candidate for a long acting therapy in patients with hemophilia A. One study showed that vWF can be modified with polyethylene glycol (PEG) resulting in prolonged survival in circulation while

maintaining the natural factor VIII stabilizing function of the molecule. In vivo analysis showed the pegylated vWF protein can be used to improve survival time of co-administered recombinant factor VIII in mouse models. Clinical studies will be conducted to confirm these results.

Clinical Data Suggest Decreased Bleeding Risk In People With Severe Hemophilia A While Maintaining Factor VIII Levels Above One Percent

Geneva, Switzerland, July 11, 2007 – Baxter today announced the presentation of findings from the ADAPT (Analysis of Data from ADVATE® Prospective Trials) study program database showing a statistically significant relationship between the duration of time spent with factor VIII blood levels below one international unit per deciliter (1 IU/dL, one percent of normal factor VIII

level) and an increase in the annual bleed rate in people with hemophilia A. The findings from ADAPT suggest that maintaining trough levels above 1 IU/dL with prophylactic therapy may decrease the number of bleeding episodes, particularly in children.

“Until now there has been insufficient clinical evidence to demonstrate that factor VIII levels less than 1 IU/dL are associated with increased bleeding in patients receiving prophylaxis for the management of hemophilia A,” said Peter W Collins M.D., FRCP, FRCPATH, Department of Haematology, University Hospital of Wales, Cardiff, U.K. “These results suggest that decreasing the amount of time a patient spends with factor VIII less than 1 IU/dL will reduce the number of bleeds. This can be achieved in part by improving adherence to prescribed prophylaxis, while measurement of trough factor VIII levels in some patients may help individual tailoring

of factor VIII dosing regimens.” Dr. Collins presented data from the ADAPT group showing an analysis of 48 children (one to six years of age) and 100 adolescents and adults (10 to 65 years of age) with severe hemophilia A and factor VIII levels less than 1 IU/dL who participated in ADVATE clinical trials. All participants were initially evaluated in a 48-hour pharmacokinetic study to measure their rate of clearance of ADVATE prior to initiation of prophylactic therapy. The 10 to 65 year old group was treated for 75 exposure days on a fixed prophylactic regimen of 25-40 IU/kg 3-4 times a week irrespective of bleeding. Prophylaxis could be modified by the physician (or investigator) for the one to six year old group.

By analyzing individual pharmacokinetic data and doses infused, Collins and coauthors were able to estimate the median number of hours per week spent below the 1 IU/

dL trough level for each population, 19.7 hours and 16.5 hours for the one to six year old and 10 to 65 year old groups respectively. Subsequent comparison with bleed frequency for each group found that in the one to six years of age group, the time below 1 IU/dL while on prophylaxis was associated with increased incidence of traumatic and spontaneous total bleeds ($p < 0.0001$). Similarly in subjects that remained on a fixed prophylactic regimen in the 10 to 65 year age group, the duration of time below 1 IU/dL was associated with increased total and joint bleeds ($p < 0.02$).

Additionally, a poster presentation of data from ADAPT showed that bleeding patterns in people with severe hemophilia using standard prophylaxis therapy vary according to age groups. For both adolescents and adults, joint bleeds were more likely to occur in the summer, possibly due to increased physical activity. Furthermore, in patients on

a Monday-Wednesday-Friday dosing schedule, a greater number of joint bleeds occurred on Sundays, reaching statistical significance in adults (18 to 65 years of age). The results support the concept of individual tailoring of prophylactic regimens according to activity and bleeding patterns.

It is important to note that prophylaxis is not an approved therapy regimen in some countries, including the United States. On demand is the approved dosage regimen for most factor VIII therapies in the United States.

Baxter Receives FDA Approval for 3000 IU Dosage Strength of ADVATE® for Hemophilia

Baxter Healthcare Corporation announced that the U.S. Food and Drug Administration (FDA) has approved a new 3000 IU (5mL) dosage strength of ADVATE® [Antihemophilic Factor (Recombinant), Plasma/Albumin-Free

ReFacto at your service— you deserve it.

**Enroll in the Trial Prescription
Program to receive a complimentary
supply of ReFacto.***



For more information, call the Trial Prescription Program administrator at 1.800.710.1379, Monday through Friday, 9:00 AM to 5:00 PM eastern time.

*Please note that patients currently receiving ReFacto and/or those who have participated in previous trial prescription programs for ReFacto are not eligible.

Method]. The dosage strength will be available to patients in the United States beginning in August 2007.

As each person with hemophilia A has different needs when it comes to infusions, it is important to have a variety of dosage strengths from which to choose. "The new 3000 IU dosage strength vial will offer people with hemophilia A more flexibility in incorporating ADVATE into their therapeutic routines," said Larry Guiheen, President, North America region, Baxter Bioscience. "Baxter is committed to expanding the ADVATE product line in order to streamline the process of infusion for patients, allowing it to fit more easily into their lives." Patients and caregivers in the United States can obtain more information on ADVATE, including full prescribing information, at http://www.advate.com/pdf/prescribing_info_english.pdf.

Editor's Note: The above press releases are not reprinted in their entirety. Please visit the website listed for complete details.

ADVOCACY

By Nancy Patrilla

Do you ever wonder what it would take to make you an advocate for something? I think some people are born with the "advocacy gene" while others have to cultivate it. Novo Nordisk, in their newsletter called Voices Uninhibited has some good articles on becoming an advocate. In the situations explained in the newsletter, the advocacy is related to medical needs; but the guidelines could be used for any situation. I think most people are advocates and don't realize it. Have you ever stood up for your child with a school official, a doctor or nurse, insurance representative, or just in daily life? That is being an advocate!

Novo Nordisk had a very good list of things to remember when being an advocate. I know from personal experience that when someone is threatening (or what I perceive as threatening) my child or children, I can get aggressive (way beyond assertive!) very quickly. Below are the keys they suggested for being an advocate:

- Believe in yourself and your cause!
- Realize that you have rights.
- Discuss your concerns with others.
- Learn as much as you can.
- Be persistent, but still be nice.
- Keep records of everything.
- Develop strong partnerships with health care providers.
- Ask for help.
- Help others.
- Follow up.
- Keep a good sense of humor!

Being a successful advocate is very rewarding. Even if you never know the impact you have on other peoples' lives, the education you provide to others on bleeding disorders



NEW 2000 IU
Kogenate® FS with
BIO-SET®

NEW Small
Grab & Go
Package

For more information, please contact your local Bayer Health Care Account Executive, Nancy Golden, at (612) 810-1186, or by email at nancy.golden.b@bayer.com.

Kogenate FS
Antihemophilic Factor (Recombinant)
Formulated with Sucrose
with **BIO-SET®**
Needleless Reconstitution System

 Bayer HealthCare
BAYER, the Bayer Cross, and Kogenate are trademarks of Bayer.
BIO-SET is a trademark of Biotest SAS.
©2007 Bayer HealthCare LLC All rights reserved. Printed in USA. 8/07 05071

can only help our community!

The above information has been paraphrased from the Summer 2007 issue of the Voices Uninhibited newsletter published by Novo Nordisk.

2007 HEMOPHILIA SUMMER CAMP

by Karla Watkinson, RN

2007 Hemophilia Summer Camp was held on June 17-22. We had 63 campers attend; 43 were children with a bleeding disorder while the remaining 20 were either siblings or guests.

Once again, camp was a very rewarding experience. We had an amazing number of kids learn about their bleeding disorder and how to prepare, administer and complete some aspect of home therapy. The campers received certificates for the "P&A Award" (Preparation and Administration), "Mini-Stick Award" (successful in completing P&A, and "sticking" another person), or the "Big-Stick Award" (successful completion of P&A, "sticking" someone else as well as themselves). The awards were based on the area(s) they were able to complete.

Activities the campers participated in throughout the week included a Pizza Party, Navigating Hemophilia (working with compasses), campfires, geocaching, building a wooden toolbox, singing, swimming, snorkeling, watching movies, dancing and singing, and learning about Mother Nature. Some campers even built cabin boats (had to support a camper or staff member)! Check out a sample of The Camp Chronicle (a daily newsletter while at camp) near the back of this newsletter.

The field trip highlight for the entire camp was our trip to Bell's Farm where the activities included fishing, kayaking, and swimming. It was the most ideal setting and a perfect day! Other field trips included an overnight adventure for the campers 12 and older to Dubuque, Iowa, for Knight's Crossing, a youth team-building experience, and an overnight stay on the William M. Black boat at the National Mississippi River Museum and Aquarium. While the "older" campers were gone, campers under 12 went to Planet X for bumper cars, games, laser tag, rock climbing, miniature golf, and many more attractions.

On the last day of camp, after the talent show, we had a dedication ceremony celebrating the new outdoor pavilion that was built with donations from Hemophilia of Iowa. Hemophilia-Bleeding Disorder Summer Camp would not have happened without the support, donations and contributions from many people and organizations.

We would like to say THANK YOU to: Hemophilia of Iowa, Inc., the Darrel Bell Family, Bayer, Baxter,

ARJ, Michael and Roseanne Deahl, J. C. Cox, David and Deb Melhado, The Goedken Family in memory of Janet Goedken Loveth, BioRx, Mid-West Cornerstone, Coram, Caremark, Option Care, Critical Care Systems, Hemophilia Health Services (Medco-Acreedo), Wyeth, CSL Behring LLC, and the University of Iowa Hemophilia Home Care Program. A special thanks also goes to Donald Pirrie, the entire Camp Tanager Staff and the Board Members of Hemophilia of Iowa!

FAMILY CAMP 2007

by Tami Bullock, RN, BSN

Our second Family Camp was held August 11-12. Family camp was started last year for children ages 3-6 (and their families) who are dealing with a bleeding disorder. This family experience allows parents and children to gain a better understanding of the summer camp experience. It also gives adults the opportunity to meet and visit with others who share similar experiences.

Ten families attended the fun-filled weekend. This was double the number



of last year's attendees. The weekend was packed with fun, games, group discussions, swimming, and, let's not forget, HEAT!! Some other activities included a Pirate hunt, campfire, relay races, a treasure hunt, and BBQ in the new pavilion. We watched the videos, "ABrightFuture" and "ABrightFuture, The Extended Family." Discussions following the video presentations were facilitated by Joe, Sal, and Dana from Inalex Communications. A special thank you to Donald Pirrie, Camp Director, and all of the camp staff for organizing activities, feeding us very well, and making the weekend such a success. Another big thank you goes to Inalex Communications, Joe, Sal and Dana, for coming to Iowa and assisting our group. Last, but certainly not least, thank you to Hemophilia of Iowa and everyone who participated faithfully in the Camp Super Fly contest. Family camp and the new pavilion at Camp Tanager would not have been possible without the '05 and '06 Camp Super Fly awards.



By Kari Atkinson

The First Step group has been busy the last few months. Our first event was at the end of June with a Summer Education Day. This was sponsored by BioRx and Bayer Healthcare. The venue was held at the Adventureland Inn Hotel where we had a great lunch. "Back to School Basics" was our educational theme.

Parents learned helpful tips and ways to deal with their schools and daycare environments. Attendance was AWESOME! One of the best things to see was all of the interaction that went on during and after the session between the parents. I think I can speak for all the families when I say that we made lasting friendships and can't wait to see our new friends at upcoming events. We finished the day having fun at Adventureland. Each family was given tickets to enjoy the park. My family stayed until the park closed at 10 p.m.. Needless to say, we were exhausted on Sunday and slept in. A big Thank You goes to everyone who attended and especially to our sponsors—Nancy Golden with Bayer Healthcare and Bill Laughlin with BioRx.

A "road show" was our second, third and fourth events on "Navigating the ER." These sessions were held during the month of July in Davenport, Des Moines and Cedar Rapids. These were all within seven days so the week was fast paced with great camaraderie and education wrapped into one package. We had people of all ages attend, and the interaction was very enlightening. Again, thank you to our sponsor, Peggy Wier with Baxter BioScience, for offering this program to our group!

If anyone does not know what the benefits are to being involved in First Step or are interested in obtaining more information regarding our First Step group, please feel free to contact the HTC or any one of the parent coordinators.

Biologics for Life™ **ZLB Behring**

For Maximum Convenience...
Helixate® FS and Mix2Vial™ are now
 packaged together!

MIX2VIAL™
 (a needle-free transfer device)

Helixate® FS
 Antihemophilic Factor (Recombinant)
 Formulated with Sucrose
Lets Boys Be Boys™

Mix2Vial is a trademark of Medinap Medical Projects Ltd.
 Helixate® FS is manufactured by Bayer HealthCare LLC for ZLB Behring LLC.
 ©2007 ZLB Behring LLC 1023 First Avenue, PO Box 61501, King of Prussia, PA 19406-0901, USA
 www.ZLBBehring-US.com ID#102-13445C 1/0007

The parent coordinators are:

Jill Nolte
319-213-1009
Mary McCarthy
641-658-2783
Kari Atkinson
866-464-8061.

We also want to Thank the First Step Platinum Sponsors, Bayer and Baxter; and Gold Sponsor, CSL Behring. We appreciate all of your support!

YOU ARE INVITED...

By Shane Kelley

Hemophilia of Iowa Board of
Directors Meeting

Date: November 10, 2007

Time: 9 am - 4 pm

Where: Beck's Sports Brewery
3295 University Ave
Waterloo, IA

U.S. NATIONAL ARCHERY CHAMPIONSHIPS

By Nancy L. Patrilla

What do people from all over the world, Pikes Peak, Para-Olympic contestants, former

Olympians, resident athletes, hopeful Olympians, and a blind person have in common?

All were in Colorado Springs, CO, the first week of August to shoot archery—lots of archery! Over 500 people, ranging in age from junior high to senior citizens were there. During our six days and nights in the foothills of Pike's Peak, Vance and Matt concentrated on shooting, technique, equipment, wind direction, staying dry (it rained almost every day, and unless there is lightening, the archers keep on shooting), and staying hydrated because when it wasn't raining, the temperature was in the 90's everyday.

Vance and Matt both shot what is known as the FITA round. They shot with a recurve bow and their fingers (as opposed to a compound and a release). They shot at 90 meters (the length of a football field), 70 meters, 50 meters, and 30 meters. They also participated in a "clout" shoot (180 yards) as well as a team shoot. Both also qualified to stay over on Saturday to shoot in the sudden death Olympic round. Matt placed 40th in his class for the week, and Vance placed 6th in his class. They shot more than 200 scoring arrows over the

course of the three tournaments (not counting the arrows shot for practice before and after each day's shooting). Both shot personal bests and were happy they attended the tournament.

My guess is that next year, we will once again be back at the foot of Pike's Peak for another week of intense archery!

YOU CAN HELP...

The United Way campaign is underway for 2007. Did you know you can write in a charity as long as they have a non-profit status? Well, Hemophilia of Iowa is a very deserving, non-profit organization!

Would you consider giving to Hemophilia of Iowa when you are deciding on any donations you want to make through United Way? If you have attended any of the many events sponsored by our chapter, you know your money goes to a good cause. Contact Kari Atkinson if you have any questions about how to designate HEMOPHILIA OF IOWA. She can be reached at the phone number listed on the Board of Directors page at the back of this newsletter.

If you decide to donate to Hemophilia of Iowa, please let either Kari or Dawn Humburg (our Treasurer) know. That way they can be watching to make sure the money gets to our organization in a timely manner. Thanks for helping!



GRANTS!!!

We have recently received two grants from two different companies.

The companies are:

Alliant Energy Pendar

The grant from Alliant Energy was given through the Alliant Energy Foundation in honor of Mike Welsh attaining 30 years of service with Alliant. Alliant Energy invites us to visit their website at www.alliantenergy.com/foundation

The grant from Pendar is at the request of Becky Welsh. Mike and Becky are grandparents of Brody, a member of the Hemophilia of Iowa community.

Thank you, Mike and Becky, for thinking of us!!!

2007 SCHOLARSHIP WINNERS NAMED

Hemophilia of Iowa proudly announces the recipients of the 2007 Scholarships for post-high school education. This year we are very pleased to be able to tell you that your fundraising efforts enabled our chapter to award a total \$20,000!

Below is a list of the names,

the amounts received and where the individual is going to school.

THANK YOU

By Wendy Baker

My son, Alex, and I would like to thank Hemophilia of Iowa once again for supporting our family in our growing endeavors. We consider Hemophilia of Iowa and the University of Iowa Hemophilia Center as part of our family. Without the individuals behind both programs, raising our sons to be the fine young men they are would have been complicated and scary.

Now, as I pursue a career in the field of nursing, and our oldest son heads off for his first year of college, Hemophilia of Iowa once again is with us. We both want to thank Hemophilia of Iowa for the financial scholarships of \$1,500 and \$800 for the 2007/2008 school year. I have chosen to further my education in the medical field after working in childcare and social work for twenty years. Our sons' medical histories and the caring medical professionals in our lives have deepened my passion for helping families with genetic disorders. Our son has also chosen a helping field in the area of criminal justice. We're sure the professionals who have touched

his life have had a great influence on his college and career choice.

Again, thank you from our entire family for your financial and emotional support.

THANK YOU

By Ashley Carlson

I would like to thank all of you for the scholarship that I received from Hemophilia of Iowa. It definitely will be put to good use. I am in the nursing program at Iowa Central Community College and you all know that it can get pretty expensive. That is why I am so grateful for the scholarship. The scholarship will go towards paying my tuition and books. So, once again, Thank You!

THANK YOU

By Ryan Hutchins

Thank you for your recent letter notifying me of the scholarship award from Hemophilia of Iowa. I am certain there were many deserving applicants for these awards, and I am humbled and deeply appreciative of your consideration of me for this scholarship. Hemophilia of Iowa serves as an important resource for many

Scholarship Recipient	Amount	College or University	City	State
Nickolas Folkerts	\$1,500.00	University of Northern Iowa	Cedar Falls	IA
Bret Fynaardt	\$1,500.00	Kirkwood Community College	Cedar Rapids	IA
Alex Baker	\$1,500.00	University of South Dakota	Vermillion	SD
Rhyan Wing	\$1,500.00	Iowa Central Community College	Fort Dodge	IA
Timothy Treichel	\$1,500.00	University of Iowa	Iowa City	IA
Matthew Patrilla	\$1,500.00	Allen College	Waterloo	IA
Benjamin Meyer	\$1,500.00	Iowa State University	Ames	IA
Bryce Kubik	\$1,500.00	Des Moines Area Community College	Ankeny	IA
Ashley Carlson	\$800.00	Iowa Central Community College	Fort Dodge	IA
Keslie Humburg	\$800.00	University of Iowa	Iowa City	IA
Wendy Baker	\$800.00	St Lukes College	Sioux City	IA
Erin Reichle	\$800.00	Capri College	Dubuque	IA
Maria Reichle	\$800.00	Clarke College	Dubuque	IA
Joseph Reichle	\$2,000.00	University of Iowa	Iowa City	IA
Ryan Hutchins	\$2,000.00	University of Iowa	Iowa City	IA
Brad Jones	\$1,500.00	South Dakota State University	Brookings	SD
Total Awarded	\$21,500.00			

Iowans who, like me, require support, information, and guidance on issues related to our unique medical needs. I look forward to meeting you and others on the committee to further share my appreciation for this honor.

INTERESTING INFORMATION

A Swine Sensation

Protein from the milk of transgenic pigs could be a revolutionary treatment for hemophilia

Since 1987, William Velander, chair of chemical & biomolecular engineering, has been researching safer, low-cost treatments for hemophilia. His efforts have resulted in genetically engineered pigs with the potential to produce large amounts of Factor VIII and Factor IX in their milk. Velander, the D.R. Voelte and N.A. Keegan Endowed Chair in Engineering, and a team of researchers

will test the pig-derived Factor IX coagulant in hemophiliac dogs during the next two years. So far, the tests in vitro and in hemophiliac mice have been highly successful, and Velander believes clinical trials in humans will begin within five years. Velander, whose background is in biochemistry and biomolecular engineering, described his journey into hemophilia research as serendipitous. He formed a close relationship with coagulation science specialists during his undergraduate and postgraduate studies and became fascinated with the idea of combining engineering and medical knowledge to treat blood disorders. He began his research as a professor at Virginia Tech University. Velander was assisted by Kevin Van Cott, a doctoral student from Purdue University who is now an associate professor of chemical & biomolecular engineering at the University of

Nebraska–Lincoln. Velander and Van Cott formed a partnership with the American Red Cross to produce genetically engineered versions of anti-hemophilic factors VIII and IX. While research for Factor IX is three years ahead of research for Factor VIII, collaboration with University of Michigan researchers Randall Kaufman and Steven Pipe has accelerated the progress on a therapy for hemophilia type A.

Velander's first step was to isolate the hemophilic factor in human blood. At first, researchers believed they could use a monoclonal antibody to capture the protein in human blood, and then purify it to eliminate viruses. However, they decided that although the process was safe, the supply would still be inadequate. Using a genetically engineered animal cell was the best way to increase the abundance of Factor IX. They had to find the perfect animal—and the perfect cell. Velander



When you need us, Baxter will be there.

Through Therapies

Providing innovative recombinant factor, plasma-derived, and inhibitor management therapies highlights our commitment to choice and illuminates our investment in research and development.

Through Participation

Offering initiatives for patients, families, physicians, and nurses and supporting local and national organizations and community events, in addition to volunteering.

Through Progress

Improving current therapies and developing new and better ways to manage hemophilia A—innovations inspired by listening to you.

For more information on Baxter programs and services, visit www.thereforyou.com.

There when you need us

Baxter

Baxter, Advoy, Camp SuperFly, Factor Assist, and www.thereforyou.com are trademarks of Baxter International Inc. ©Copyright (January 2007), Baxter Healthcare Corporation. All rights reserved. HYL2652

said researchers considered several criteria: the animal needed the ability to produce complex proteins because Factor VIII and Factor IX are two of the most complex proteins known; the animal's biochemistry had to be similar to humans'; the cell had to be stable and prodigious in its production setting; and the molecules needed a long circulation lifetime once inserted into the body.

In the 1980s, advances in breast cancer research proved that mammals' mammary glands make and secrete large volumes of protein. Researchers at universities in the United States, the Netherlands and Scotland were engineering transgenic cows, sheep and goats and using the milk to produce therapeutic proteins. Velander considered using traditional dairy livestock, but found that ruminants' mammary glands placed a problematic molecular signature on

proteins made in milk. Any protein bearing this signature wouldn't survive in the human body long enough to be effective, Velander said. His decision to obtain milk proteins from a pig was unorthodox. However, Velander said, the biochemistry of pigs is the closest to our own. Pigs produce less milk than most dairy animals, but that doesn't matter. "Pig proteins are so concentrated and potent that only a tiny amount needs to be injected in the body to work," he said.

Velander produced genetically engineered cells by inserting the human Factor IX gene into the animal cell. Figuring out how to reproduce the cell was a challenge. Reproducing cells in a stainless steel bioreactor prevented disease and contamination. However, Velander found that a bioreactor was 100 to 1,000 times less effective than cells living within tissue. This is because fewer cells

can grow and receive nutrients in a culture setting compared with tissue. Thus, Velander used the natural productivity of tissue as a bioreactor setting—in this case, the mammary gland of a transgenic pig. To produce such an animal, he inserts the Factor IX gene into several freshly fertilized one- or two-cell embryos. The embryos are transferred to a surrogate mother pig. Through its natural gene maintenance machinery, the cell slices the Factor IX gene into the pig's chromosomes. The gene becomes a transgene, or a permanent part of the unborn pig's heredity. Ten to 30 percent of a litter derived from these embryos is transgenic. Once a transgenic pig reaches maturity, they are bred with ordinary production pigs. After farrowing, the pigs are milked for two 50-day lactation cycles. Each sow typically yields 100 to 300 liters of milk annually.



YOU'RE NOT JUST A NAME.

The Hemophilia Homecare Program at University of Iowa Hospitals and Clinics is a homecare program that understands the meaning of quality, personalized service. We meet all your hemophilia homecare needs with quality products and services at a lower cost. We get to know you as a person, not just as a name. Knowing you better means understanding your needs.

UI Hospitals and Clinics Hemophilia Homecare Program. Call us toll free at 866-219-9117 to find out how we can help you today.



University of Iowa Health Care

Our specialty isn't
what we do,
it's how we do it.

CAREMARK®
It all starts with care™

- Experience That Counts
- Our Commitment to You
- Safety You Can Depend On
- Service You Deserve
- Integrity You Can Trust

Holly Haskell
1-800-670-6782 x3230
1-314-726-5805
www.caremark.com

The first pig able to produce Factor IX was born in 1994. Her milk contained about 75 times more Factor IX than human plasma. With optimization in molecular design of the transgene, recent pigs have produced more than 100 times the amount of Factor IX found in human plasma. Velander estimates that milk from just 100 to 200 transgenic pigs could produce enough Factor IX to meet the world's demand for hemophilia type B therapy. The first Factor VIII pig produced as much as 20 times the amount of the protein found in human blood. Newer versions of this pig, expected to become available within two years, should produce high levels of the protein needed for hemophilia type A treatment. Velander acknowledges that the public is skeptical of the benefits of cloning and genetically modified animals. His pigs live in a secluded facility in the mountains of Virginia to shield them from disease. Visitors are required

to shower and change into clean clothing before entering. "The animals are extraordinarily well taken care of and arguably have a higher quality of life than most people in this world," he said. "Even activists have been generally agreeable that this kind of effort is a win-win for the animal and people." About 100,000 people worldwide have hemophilia type B, and 500,000 have hemophilia type A. The World Federation of Hemophilia estimates that the real total may be two or three times higher, but many hemophiliacs die during infancy because they're not properly diagnosed and treated. And while Americans have difficulty stomaching the cost of treatment, people in Third-World countries can't afford treatment at all, Velander said. He estimates that his new drug would cost \$2,000 to \$10,000 annually. For a severe hemophiliac living in the United States, plasma treatments cost up to \$200,000 annually. The cost of

drug therapy is several times higher. "While the U.S. can certainly benefit from this technology, it's important to note that the biggest impact will be in lesser developed countries where 80 percent of the dire need exists," Velander said. "This has the potential to give them access to sophisticated healthcare they don't have now." Researchers will test the potent, pig-based coagulant in hemophiliac dogs, and Velander said the results in hemophiliac mice have been promising. In September 2005, UNL received a five-year grant in excess of \$10 million from the National Institute of Health's (NIH) National Heart, Lung and Blood Institute. The grant is being used to complete preclinical research in animals. If everything goes according to plan, Velander will seek approval from the federal Food and Drug Administration to do clinical evaluations in humans within five years. The researchers also are studying new ways to administer the drug because chronic intravenous injections are dangerous, especially in young children and infants. He hopes the drug can be administered through the mouth, nose or trachea. This may be possible because of the abundance of medicine that transgenic pigs provide. "This would be a welcomed miracle for the parents of hemophilic infants," Velander said.

RECOGNITION

On behalf of all of the HOI Board of Directors I would like to extend a sincere Thank You to Peggy Wier. Peggy served on the Board of Directors from September 2005 to September 2007 as an industry member. When we had the Board change of leadership in December of 2005, Peggy stepped up to the plate and provided leadership and guidance for all of us who were new

ARJ *Infusion* SERVICES

Where *caring* is ...

- Award Winning Nursing
- Licensed Home Health Agency
- Pharmacy Onsite
- 24 Hour On-call Service
- Reimbursement Experts
- Infusion Education for Patients and Families



Toll Free 866.451.8804
www.arjinfusion.com

Lisa Sackovich, RN, BSN, CRNI
President and Owner

...the **ULTIMATE** Factor.

Specializing in...

Hemophilia

Bleeding Disorders

Von Willebrand's Disease

to the Board. She took an incredibly active role in the advocacy group, the Camp SuperFly committee, chairing the information committee, which included working on the newsletter publication details and also the website. We do not want to forget her leadership as one of the chairs for the last two annual meetings. Our Board is staffed entirely by volunteers, and Peggy never did anything less than 125% when she was involved. We, as a Board, are extremely grateful for all of her loyalty, guidance, hard work, determination and professionalism.

Peggy, we are going to miss you; and we look forward having you attend our upcoming events and enjoy the festivities as a participant instead of the chair.

THANK YOU, PEGGY, FOR ALL YOU HAVE DONE FOR HOI!!!

AND FINALLY

Did you know that there is a website designed by mothers of children with bleeding disorders? It is called MUMS – Mothers United Mission for Sons. Two moms launched the homecare-sponsored site in 2005 to help provide networking, education, and resources to other mothers like themselves.

To learn more, visit the MUMS web site at www.thewordismums.com


Please note that the annual membership application in this newsletter is for 2008. If you

pay your dues now, it will be considered your 2008 membership. There are some great benefits to being a member of Hemophilia of Iowa! In our next issue we will highlight some of the programs and events that went on at our annual Education Weekend, which was held in Des Moines in September. If you missed it, you really should consider attending the next time. Childcare is offered, lodging is covered; meals are furnished; there are visits with old and new friends; and free raffle prizes (and there are always awesome prizes!). What is not to like about a weekend like that? Have a great fall!

Kid's Corner



Insectopia

Fun Facts

Did you know?

- <Dragonflies can fly up to 50 mph!
- >Ants don't sleep!
- >Night butterflies have ears on their wings so they can hear their predators!
- >Honeybees have hair on their eyes!



Color Me!

Word Find



- MOTH
- DRAGONFLY
- BEE
- ANT
- MOSQUITO
- BUTTERFLY
- WASP
- BEETLE
- CATERPILLAR



B	U	T	T	E	R	F	L	Y	X	D
E	B	A	E	K	T	B	W	U	I	R
E	L	S	I	Q	N	V	P	E	F	A
H	I	L	J	M	K	G	R	D	C	G
W	X	Z	M	O	S	Q	U	I	T	O
A	Y	P	K	T	E	I	Z	H	M	N
S	T	B	C	H	Q	A	I	U	O	F
P	G	A	O	B	E	E	T	L	E	L
X	Y	N	A	Q	Z	K	H	D	F	Y
C	A	T	E	R	P	I	L	L	A	R



Created by: Keslie Humburg

The Camp Chronicle

June 22nd, 2007 • Camp Tanager • Friday • Chance of showers & storms. Hi of 80



TEAMWORK & TRUST, IT'S A CAMP THING!

Campers from cabins 5&6 returned from Dubuque yesterday morning after an overnight field trip to remember!

The outing started with an exciting teamwork and trust activity called Knight's Crossing—bringing campers together to work as a team, trust each other, and figure out complex challenges. Campers and staff reported that the activity was very rewarding and a lot of fun. The evening consisted of an overnight stay in a steamboat on the Mississippi, and a trip to the Grand Harbor waterpark. Everyone arrived back at camp tired, but ready to jump in to the remaining camp program!



FRIDAY'S CROSSWORD PUZZLE!

A C T I V I T I E S G I T W C
 O J R S S M O T O O R A U B O
 T E T O P M M V Q N Y U R W U
 P C F M E Q L H P G Y F R L N
 C G A R M B C C T S Q I K J C
 A R D R J I F G D S U T G J E
 M O P P N T G F S T I K S N L
 P T D S O I P J H G F B N F O
 F E O T P R V E N P I Y H E R
 I E J N N I T A L Y F E M J S
 R T Y P I B D C L O D G E W P
 E E H J G K P E R B J G Q K V
 S F L I E S E W R P K B V X Z
 O H E H K W O K G S D R I B V
 R J H P E Y G W M O P H Q G B

Can you find these camp words? Look forwards, backwards and diagonal. Good Luck!

- | | | | |
|------------|----------|-------|-------|
| ACTIVITIES | CARNIVAL | SONGS | LODGE |
| COUNSELORS | SPIDERS | BIRDS | SKITS |
| CAMPFIRES | FLIES | | |

HOT SHOTS



A grand finale to a great week at camp—Campfire is always a big hit with campers and counselors!



Griffin finds another piece of the hidden treasure map!



Chris is ready to dance!



Cricket enjoys some Karaoke



Jacob & Joshua from Cabin 4 spent time yesterday evening learning how to poke nurses Tami and Karla!



Great job to Jacob, Joshua, and to everyone for their 'big stick' and 'mini stick' awards this week!

Hemophilia of Iowa Board Members

President

Kari Atkinson
PO Box 415
Central City, IA 52214
caklatkinson@aol.com
H) 866-464-8061
C) 319-721-3964

Vice President

Shane Kelley
22930 20th Street
Fairbank, IA 50629
ssckelley@iowatelecom.net
H) 319-635-2839
C) 319-239-3948

Treasurer

Dawn Humburg
1002 6th Avenue SW
Humboldt, IA 50548
Humbug5@mchsi.com
H) 515-332-5069
C) 515-368-2508

Secretary

Emily Wiedman
1604 Olive St
Cedar Falls, IA 50613
Emily_Weidman@hotmail.com
H) 319-277-7162
C) 319-269-8509

Debbie Dow
1074 190th Street
Rockford, IA 50468
dowbldrs@omnitelcom.com
H) 641-749-2553
C) 641-425-8318

Carol Meyer
2647 G Avenue
Ladora, IA 52251
cmeyer@netins.net
H) 319-655-7304

Cathy Treichel
2551 Holiday Road Apt. A-7
Coralville, IA 52241
Meow1ct@aol.com
C) 319-358-9868

James Van Bruggen
317 NE Trilien Dr #106
Ankeny, IA 50024
James.van.bruggen@gmail.com
H) 515-450-0484

Tom Recker
3034 Cornell Avenue
Iowa City, IA 52245
thomas-recker@uiowa.edu
H) 319-341-0257
C) 319-330-5956

Maria Ormord
1803 Oakland Avenue
Cedar Falls, IA 50613
mruth@cfu.net
319-268-0676

Brian Unruh
849 Latham Place
Cedar Falls, IA 50613
bunruh@aea267.k12.ia.us
H) 319-266-9393

Bill Laughlin (Industry/Vendor
Rep)
3024 Timberline Drive
Riverside, IA 52327
blaughlin@biorx.net
C) 319-325-5080

Mark Wiener (Industry/Vendor
Rep)
114 Warner Way
Mahtomedi, MN 55115
mark.wiener@cslbehiring.com
C) 612-803-7684

Jim Brown (Industry/Vendor Rep)
7309 Baldwin Avenue
Lincoln, NE 68507
jim@mwcornerstone.com
H) 402-466-7363
C) 402-440-2882

Terry Morrow (Industry/Vendor
Rep)
109 E. 3rd Street
Lake Park, IA 51347
terry.morrow@hemophiliahealth.
com
C) 712-330-6073

Hemophilia of Iowa
Membership Application

Name: _____

Address: _____

Phone #: _____ Cell #: _____ E-mail: _____

Please circle the best option for you:

Best time to contact me: AM/PM

Would you be willing to serve on a committee? Yes No

Membership January 1 - December 31, 2008
Single, Family, Industry Representative, & Friends of Hemophilia of Iowa \$20.00

Family includes residents in the same household with dependent children up to the age of 25. (Dependent children do not have to reside in the parent's home if away at school or living on their own.) Family would be a sister, brother, grandparent, aunt, uncle and cousin to the person who has a bleeding disorder. Friends of Hemophilia of Iowa are people who do not have a relative with a bleeding disorder but are support people and friends of those who do have a bleeding disorder.

I would like to make an additional donation of \$_____ (this is tax deductible).

Please complete the following information so Hemophilia of Iowa can be of best service to you.

What is your association to the bleeding disorder community?

- I have a bleeding disorder or my spouse has a bleeding disorder.
- I am a parent of a child with a bleeding disorder.
- I am a relative of a person with a bleeding disorder.
- I am a friend/support person for someone who has a bleeding disorder.

If you are a relative or friend/support person for someone with a bleeding disorder, please list the last name of the person who has the bleeding disorder: _____.

If you have a child with a bleeding disorder, Hemophilia of Iowa now has a program called First Step. This program is designed to provide a mentor to families with a child(ren)(ages 0-7) who has a bleeding disorder.

Mentors are parents of child(ren) who have a bleeding disorder ages 8 and older.

- I would like to join First Step and have a mentor.
- I have a child eight (8) years or older and would like to be a mentor.
- I would like more information before I decide to join. Please call me.

Please do not let cost of membership prevent you from joining Hemophilia of Iowa. Contact Kari Atkinson, HOI President at 1-866-464-8061 for confidential financial assistance. This membership scholarship program is available for people directly affected by a bleeding disorder and their caregivers.

PLEASE MAIL MEMBERSHIP APPLICATION AND ANNUAL DUES (PAYABLE TO HEMOPHILIA OF IOWA) TO:

EMILY WEIDMAN, HOI SECRETARY, 1604 OLIVE ST, CEDAR FALLS, IA 50613

IF YOU WISH TO PAY VIA CREDIT CARD, PLEASE COMPLETE THE BELOW INFORMATION: (CIRCLE ONE) VISA OR MASTERCARD

Card Number: _____ **Expiration Date:** _____

Name as it appears on card: _____

Address as it appears on card statement: _____

Signature of card holder: _____

Mailed by:
UIHC
Hemophilia Treatment Center
200 Hawkins Dr., 2507 JCP
Iowa City, IA 52242